About FDA

Office of Combination Products

The FDA Office of Combination Products (OCP) was established on Dec. 24, 2002, as required by SEC. 204 of the Medical Device User Fee and Modernization Act of 2002 (MDUFMA). The law gives the OCP broad responsibilities covering the regulatory life cycle of combination products. Specifically, the primary roles of OCP are:

  • To serve as a focal point for combination product issues for FDA staff and industry.
  • To develop guidance, regulations, and standard operating procedures to clarify the regulation of combination products.
  • To classify products as drugs, devices, biological products, or combination products and assign an FDA center to have primary jurisdiction for premarket review and postmarket regulation where the jurisdiction is unclear or in dispute.
  • To ensure timely and effective premarket review of combination products by overseeing the timeliness of and coordinating reviews involving more than one agency center.
  • To ensure consistency and appropriateness of postmarket regulation of combination products.
  • To facilitate resolution of disputes regarding the timeliness of premarket review of combination products.
  • To update agreements, guidance documents, or practices specific to the assignment of combination products.
  • To develop annual reports to Congress on the Office’s activities and impacts.
  • To provide training to FDA staff and regulated industry on combination product regulation.

The Office of Combination Products currently has 12 staff members:

  • Thinh X. Nguyen - Director
  • Patricia Y. Love, MD., MBA. - Deputy Director
  • John (Barr) Weiner, JD. - Associate Director for Policy and Product Classification Officer
  • Leigh Hayes, J.D. - Product Assignment Officer
  • Jose L. Moreno, Ph.D. - Senior Scientific Reviewer
  • Joseph Milone, Ph.D. - Senior Scientific Reviewer
  • Bibi Jakrali - Management Analyst
  • Bindi Nikhar, MD. - Associate Clinical Director
  • Melissa Burns - Senior Program Manager
  • Diana Yoon, Ph.D. - Senior Scientific Reviewer
  • Maryam Mokhtarzadeh, MD- Senior Medical Officer
  • Danita M. Dixon- Project Management Officer

Contact FDA:

All inquiries should be sent to OCP’s central inbox, combination@fda.hhs.gov.  This inbox is monitored during business hours and your inquiry will be assigned to the appropriate OCP staff member for response.

 

Contact FDA

301-796-8930
Fax:301-847-8619
Office of Combination Products

Food and Drug Administration

WO32, Hub/Mail Room #5129

10903 New Hampshire Avenue

Silver Spring, MD 20993

Page Last Updated: 01/30/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English